文献速递瓣膜病与结构性心脏病

退变生物瓣行瓣中瓣TAVR的3年结局:PARTNER 2注册研究

3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 Registry.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

PARTNER 2瓣中瓣注册研究前瞻性纳入365例外科主动脉生物瓣症状性退变且再手术高危患者,行瓣中瓣TAVR后随访3年。3年全因死亡Kaplan-Meier估计为32.7%,需主动脉瓣再置换者1.9%;跨瓣压差、瓣口面积、反流及心功能指标均持续改善,结论为瓣中瓣TAVR与良好生存、持久血流动力学及功能和生活质量结局相关。

要点

  • 高危退变生物瓣患者行瓣中瓣TAVR,3年全因死亡估计32.7%,再置换率1.9%。
  • 跨瓣压差由基线35.0 mmHg降至3年16.6 mmHg,有效瓣口面积由0.93 cm2升至1.15 cm2。
  • 中重度主动脉瓣反流由45.1%降至3年2.5%,心功能与生活质量持续改善。

核心结论

  • 3年随访时,针对生物主动脉瓣衰败的TAVR与良好生存、持续改善的血流动力学状态以及优良的功能和生活质量结局相关。

研究设计与样本

  • 多中心PARTNER 2瓣中瓣及持续准入注册研究前瞻性纳入365例外科主动脉生物瓣症状性退变、再手术高危(主要并发症或死亡风险≥50%)患者,并获取3年临床与超声心动图随访。

主要发现

  • 3年全因死亡Kaplan-Meier估计为32.7%,需主动脉瓣再置换者占1.9%。
  • 平均跨主动脉瓣压差由基线35.0 mmHg降至30天17.8 mmHg和3年16.6 mmHg,有效瓣口面积由基线0.93 cm2增至30天1.13 cm2和3年1.15 cm2。
  • 中重度主动脉瓣反流由TAVR前基线45.1%降至3年2.5%;中重度二尖瓣反流由33.7%降至8.6%(p < 0.0001),中重度三尖瓣反流由29.7%降至18.8%(p = 0.002)。
  • 左心室射血分数由基线50.7%升至3年54.7%(p < 0.0001),左心室质量指数由136.4 g/m2降至3年109.1 g/m2(p < 0.0001)。
  • NYHA III或IV级由基线90.4%降至3年14.1%(p < 0.0001),堪萨斯城心肌病问卷总体评分由43.1升至73.1(p < 0.0001)。

临床怎么用

  • 对于外科主动脉生物瓣症状性退变且再手术高危的患者,瓣中瓣TAVR可作为改善3年生存、血流动力学及功能状态的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) for degenerated surgical bioprosthetic aortic valves is associated with favorable early outcomes. However, little is known about the durability and longer-term outcomes associated with this therapy. OBJECTIVES: The aim of this study was to examine late outcomes after valve-in-valve TAVR. METHODS: Patients with symptomatic degeneration of surgical aortic bioprostheses at high risk (≥50% major morbidity or mortality) for reoperative surgery were prospectively enrolled in the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 valve-in-valve and continued access registries. Three-year clinical and echocardiographic follow-up was obtained. RESULTS: Valve-in-valve procedures were performed in 365 patients. The mean age was 78.9 ± 10.2 years, and the mean Society of Thoracic Surgeons score was 9.1 ± 4.7%. At 3 years, the overall Kaplan-Meier estimate of all-cause mortality was 32.7%. Aortic valve re-replacement was required in 1.9%. Mean transaortic gradient was 35.0 mm Hg at baseline, decreasing to 17.8 mm Hg at 30-day follow-up and 16.6 mm Hg at 3-year follow-up. Baseline effective orifice area was 0.93 cm2, increasing to 1.13 and 1.15 cm2 at 30 days and 3 years, respectively. Moderate to severe aortic regurgitation was reduced from 45.1% at pre-TAVR baseline to 2.5% at 3 years. Importantly, moderate or severe mitral and tricuspid regurgitation also decreased (33.7% vs. 8.6% [p < 0.0001] and 29.7% vs. 18.8% [p = 0.002], respectively). Baseline left ventricular ejection fraction was 50.7%, increasing to 54.7% at 3 years (p < 0.0001), while left ventricular mass index was 136.4 g/m2, decreasing to 109.1 g/m2 at 3 years (p < 0.0001). New York Heart Association functional class improved, with 90.4% in class III or IV at baseline and 14.1% at 3 years (p < 0.0001), and Kansas City Cardiomyopathy Questionnaire overall score increased (43.1 to 73.1; p < 0.0001). CONCLUSIONS: At 3-year follow-up, TAVR for bioprosthetic aortic valve failure was associated with favorable survival, sustained improved hemodynamic status, and excellent functional and quality-of-life outcomes. (The PARTNER II Trial: Placement of Aortic Transcatheter Valves II - PARTNER II - Nested Registry 3/Valve-in-Valve [PII NR3/ViV]; NCT03225001).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Webb JG, Murdoch DJ, Alu MC, et al. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 Registry. J Am Coll Cardiol. 2019. PMID: 31146808. doi:10.1016/j.jacc.2019.03.483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。